Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neoplasms 1Motor Activity 1Medulloblastoma 1Lymphoma 1Leukemia 1Infratentorial Neoplasms 1Brain Neoplasms 1Attention Deficit Disorder with Hyperactivity 1Ataxia 1

Interventions

AZD 6244 19trametinib 5Lovastatin 5Deoxycholic Acid 4mirdametinib 3Lasers, Solid-State 3pirfenidone 2fludarabine 2binimetinib 2Vincristine 2Vinblastine 2Transcranial Direct Current Stimulation 2Specimen Handling 2Sirolimus 2Polidocanol 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2Lasers 2Lamotrigine 2Inhalation 2Everolimus 2Carboplatin 2Blood Specimen Collection 2Biopsy 2Acetylcysteine 2tipifarnib 1thymoglobulin 1talimogene laherparepvec 1pomalidomide 1peginterferon alfa-2b 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibromatosis 1 × Control Groups × CNS × Clear all
NCT05913037 2025-03-06

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

Fosunpharma

Phase 3 Active not recruiting
167 enrolled
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡